Roche Diagnostics Corporation has gained approval from Health Canada for its Cerebrospinal Fluid (CSF) assays to measure three biomarkers in adults aged 55 and over, allowing physicians to diagnose Alzheimer's disease. The Elecsys® beta-Amyloid, Phospho-Tau(181P), and Total-Tau CSF tests can be carried out on automated immunoassay analyzers available across the country. These biomarkers help track healthy processes, diagnose diseases or other health conditions, monitor responses to medication and identify potential health risks by detecting indicators of what is happening in the body. By measuring changes in these markers, medical teams can understand how quickly a patient's condition may advance or potentially predict how it may develop in the future.
Keywords: Roche Diagnostics Corporation, Health Canada Approval, Cerebrospinal Fluid Assays (CSF), Biomarkers for Alzheimer's Disease Diagnosis
Earlier diagnosis through biomarker testing enables doctors to detect patients who are facing cognitive decline due to AD thereby identifying them early enough for proper care management treatment. According to CanAge’s Dementia Cross-Country Report 2022 published last year dementia is a global challenge of truly epic proportions that requires early diagnosis and intervention as several key benefits come with early